SRR934759
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 134.98685939553218
- age_years
- 59
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.439
- TGF_BETA_SIGNALING+0.379
- TNFA_SIGNALING_VIA_NFKB+0.367
- MITOTIC_SPINDLE+0.340
- HEDGEHOG_SIGNALING+0.288
- UV_RESPONSE_UP+0.288
- KRAS_SIGNALING_UP+0.266
- PROTEIN_SECRETION+0.262
- MTORC1_SIGNALING+0.256
- ANDROGEN_RESPONSE+0.239
Top 10 suppressed
- DNA_REPAIR-0.364
- MYC_TARGETS_V1-0.290
- MYC_TARGETS_V2-0.276
- E2F_TARGETS-0.251
- COAGULATION-0.148
- IL6_JAK_STAT3_SIGNALING-0.135
- XENOBIOTIC_METABOLISM-0.101
- ANGIOGENESIS-0.077
- G2M_CHECKPOINT-0.076
- GLYCOLYSIS-0.048
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D65697C7-2DA7-43BA-ABE2-50CB08B0D126 | — | — | 0.845 |
| 2 | 1D2F3ED9-6319-4661-9E41-9DC9C8342DE1 | — | — | 0.832 |
| 3 | 093A32DA-49D0-4F4C-9000-4F47B4700F4E | — | — | 0.825 |
| 4 | 45B7816C-0A67-441C-8E80-656EAF2AD940 | — | — | 0.818 |
| 5 | 618FAB92-C578-4144-9BD0-AEE1AFBFA08E | — | — | 0.815 |
| 6 | 8F5717EC-3344-48CA-9B0C-FCDED8C0F955 | — | — | 0.799 |
| 7 | 8AACDB46-9BB3-42BA-871D-7A593F14430A | — | — | 0.777 |
| 8 | SRR934720 | — | — | 0.771 |
| 9 | 7EDF85E0-24E3-43B6-8C00-BBA39235266E | — | — | 0.749 |
| 10 | 106E2A94-0366-4D5E-894F-41117C78E18C | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.439 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.379 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.367 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.288 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.288 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.266 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.262 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.256 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.239 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.225 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| HYPOXIA | 0.215 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.209 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.202 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.196 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.195 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.192 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.186 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.157 | Inavolisib | — uncovered |